Though AAPIs make up less than 5% of the U.S. population, they account for more than 50% of the 1.2 million Americans estimated to be living with hepatitis B. Testing identifies people living with hepatitis B and helps them take steps to protect their health, including starting treatment that can delay or reverse the effects of liver damage.